Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TENX

+ Watchlist+ Portfolio

Tenax Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.42
52-Week Range
$1.31 – $19.40
Market Cap
$65.12M
P/E (TTM)
—
EPS (TTM)
-1.39
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.71
PEG Ratio
1.44
Return on Equity
-64.20%
Return on Assets
-39.54%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
14.01
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-27.05M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-37.07M

Market Snapshot

About

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market. The company is developing levosimendan, a calcium sensitizer, for the treatment of pulmonary hypertension associated with heart failure. Tenax aims to address unmet medical needs in cardiovascular and pulmonary diseases.